Nuwellis Inc. (NASDAQ: NUWE) priced a public offering of 20 million shares of common stock with accompanying warrants for gross proceeds of approximately $6 million, according to a company statement.

The medical technology company set the public offering price at $0.30 per share with accompanying warrants. The offering includes Series C Warrants and Series D Warrants, each with an exercise price of $0.30 and exercisable for five years following stockholder approval and a reverse stock split effective date.

The Series C Warrants contain a one-time reset provision that adjusts the exercise price if the company implements a reverse stock split. The Series D Warrants include a cashless exercise option allowing holders to receive shares without additional payment to the company.

The offering consisted of warrants to purchase up to 60 million Series C common stock shares and 20 million Series D warrants to purchase additional shares of common stock.

In a concurrent private placement, Nuwellis entered into warrant reprice transactions with existing warrant holders to reduce the exercise price of previously issued warrants to $0.30, subject to stockholder approval.

Ladenburg Thalmann & Co. Inc. served as exclusive placement agent for the offering.

The securities are offered under a registration statement on Form S-1 that was declared effective by the Securities and Exchange Commission on June 4, 2026, and an additional registration statement filed under Rule 462(b) on June 5, 2026.

Nuwellis develops medical technology solutions for patients with cardiorenal conditions across acute and chronic care settings.